{"nctId":"NCT05764525","briefTitle":"Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy","startDateStruct":{"date":"2021-07-19","type":"ACTUAL"},"conditions":["Pain, Postoperative","Acute Pain"],"count":285,"armGroups":[{"label":"VVZ-149 Injections","type":"EXPERIMENTAL","interventionNames":["Drug: VVZ-149 Injections"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"VVZ-149 Injections","otherNames":["Opiranserin Injections"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women who are at least 18 years of age\n* Female subjects who are not pregnant or breastfeeding\n* Subjects undergoing a planned first laparoscopic colectomy\n* Subjects classified in American Society of Anesthesiologists (ASA) risk class of I or II\n* Subjects who report the pain intensity ≥ 5 on the NRS measured after surgery\n* Subjects who have the ability to understand study procedures and communicate clearly with the investigator and staff\n* Subjects who provide written informed consent prior to participation in the study\n\nKey Exclusion Criteria:\n\n* Subjects undergoing emergency or unplanned surgery\n* Subjects who had a previous laparoscopic colectomy procedure, or who had any laparoscopic resection procedure\n* Subjects with pre-existing conditions causing preoperative pain at the site of surgery\n* Female subjects who are pregnant or breastfeeding\n* Diagnosis of chronic pain (e.g., persistent pain with the intensity of NRS ≥ 5 at baseline)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12)","description":"Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0 (no pain) to 10 (worst pain imaginable). Time-weighted Sum of Pain Intensity Difference (PID) for 12 hours post-dose (SPID 12) was estimated using the linear trapezoidal rule (L x Hour) with the PI scores assigned from Time 0 to Time 12 hours post-dose using the following formula. The theoretical SPID 12 ranges from 0 to 120. A higher value of SPID indicates greater pain relief.\n\nSPID 12 = S \\[T(i)-T(i-1)\\] × \\[PID(i)+PID(i-1)\\]/2, when PID(i) =Predose PI-PI at Time i","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.83","spread":"1.73"},{"groupId":"OG001","value":"19.89","spread":"1.72"}]}]}]},{"type":"SECONDARY","title":"Total Number of Patient-controlled Analgesia (PCA) Requests for 12 Hours Post-dose","description":"Total number of patient-controlled analgesia (PCA) requests from Time 0 to Time 12 hours was compared between the VVZ-149 Injections group and the placebo group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"10.24"},{"groupId":"OG001","value":"17.6","spread":"63.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"5.97"},{"groupId":"OG001","value":"10.1","spread":"19.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"6.88"},{"groupId":"OG001","value":"8.0","spread":"16.18"}]}]}]},{"type":"SECONDARY","title":"Total Amount of PCA and Rescue Medication Consumption for 12 Hours Post-dose","description":"Total amount of PCA and rescue medication consumption from Time 0 to Time 12 hours was compared between the VVZ-149 Injections group and the placebo group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":"28.28"},{"groupId":"OG001","value":"47.0","spread":"32.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"20.45"},{"groupId":"OG001","value":"31.9","spread":"27.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":"19.63"},{"groupId":"OG001","value":"27.6","spread":"25.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"19.64"},{"groupId":"OG001","value":"24.9","spread":"24.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":141},"commonTop":["Nausea","Post procedural fever","Vomiting","Hypertension","Haematochezia"]}}}